Drug Repurposing Against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
Sarah Aherfi, Bruno Pradines, Christian Devaux, Stéphane Honoré, Philippe Colson, Bernard La Scola, Didier Raoult
Abstract
antiviral activity against SARS-CoV-2, combined with molecular docking data and results from preliminary clinical studies. Finally, when considering all these previous findings, as well as the possibility of oral administration, 11 molecules consisting of nelfinavir, favipiravir, azithromycin, clofoctol, clofazimine, ivermectin, nitazoxanide, amodiaquine, heparin, chloroquine and hydroxychloroquine, show an interesting antiviral activity that could be exploited as possible drug candidates for COVID-19 treatment.
Topics & Concepts
NitazoxanideDrug repositioningClofazimineHydroxychloroquinePharmacologyFavipiravirContext (archaeology)AmodiaquineMedicineDrugRepurposingChloroquineAntiviral drugVirologyCoronavirus disease 2019 (COVID-19)BiologyMalariaImmunologyInfectious disease (medical specialty)EcologyPaleontologyPathologyDiseaseLeprosyCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchPharmacological Receptor Mechanisms and Effects